IP Library Granted Patent US 12,247,984
Granted Patent B2
US 12,247,984 · App. 17/127,953 · Granted Mar 11, 2025

Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use

Inventor: Scott A. Smith (White Bluff, TN)
Assignee: VANDERBILT UNIVERSITY
G01N33/686A61K39/35A61K45/06C07K16/16C07K16/18G01N33/5308C07K2317/21G01N2333/43526G01N2333/43582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,984
App. No.
17/127,953
Granted
Mar 11, 2025
Kind
B2
Abstract

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Claims (11)

1. A method of treating a dust mite-related allergic reaction in a subject comprising delivering to said subject an IgG antibody or antibody fragment, wherein said antibody or antibody fragment comprises heavy chain CDR1 SEQ ID NO: 123, heavy chain CDR2 SEQ ID NO: 124, heavy chain CDR3 SEQ ID NO: 125, light chain CDR1 SEQ ID NO: 201, light chain CDR2 SEQ ID NO: 202, and light chain CDR3 SEQ ID NO: 203.

2. The method of claim 1 , wherein the antibody or antibody fragment is encoded by clone paired heavy and light chain variable nucleic acid sequences as set forth in SEQ ID NO: 13 and SEQ ID NO: 14.

3. The method of claim 1 , wherein said antibody or antibody fragment is encoded by clone paired heavy and light chain variable nucleic acid sequences having 70%, 80%, or 90% identity to heavy and light chain variable nucleic acid sequences as set forth in SEQ ID NO: 13 and SEQ ID NO: 14.

4. The method of claim 1 , wherein said antibody or antibody fragment is encoded by clone paired heavy and light chain variable nucleic acid sequences having 95% identity to heavy and light chain variable nucleic acid sequences as set forth in SEQ ID NO: 13 and SEQ ID NO: 14.

5. The method of claim 1 , wherein said antibody or antibody fragment comprises clone paired heavy and light chain variable sequences as set forth in SEQ ID NO: 65 and SEQ ID NO: 66.

6. The method of claim 1 , wherein said antibody or antibody fragment comprises clone paired heavy and light chain variable sequences having 70%, 80%, or 90% identity to heavy and light chain variable sequences as set forth in SEQ ID NO: 65 and SEQ ID NO: 66.

7. The method of claim 1 , wherein said antibody or antibody fragment comprises clone paired heavy and light chain variable sequences having 95% identity to heavy and light chain variable sequences as set forth in SEQ ID NO: 65 and SEQ ID NO: 66.

8. The method of claim 1 , wherein said antibody or antibody fragment is a recombinant scFv (single chain fragment variable) antibody, chimeric antibody, Fab fragment, F(ab′)2 fragment, or a Fv fragment.

9. The method of claim 1 , further comprising treating said subject with an anti-inflammatory agent.

10. The method of claim 9 , wherein said anti-inflammatory agent is selected from the group consisting of a steroid, an anti-histamine, and anti-leukotriene.

11. The method of claim 9 , wherein said anti-inflammatory agent is administered chronically.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2023
From: SMITH, SCOTT A.
To: VANDERBILT UNIVERSITY
Reel/Frame 063838/0764 →
Continuity (3)
Continuation 16481165
Provisional Application 62452603 · Jan 31, 2017
Related Publication 20210382064A1 · Dec 9, 2021
References Cited (44)
US 8697079B2 · Penichet et al. · 2014 [cited by applicant]
US 8802375B2 · Sampson et al. · 2014 [cited by applicant]
US 9127251B2 · Spits et al. · 2015 [cited by applicant]
US 9238062B2 · Chen et al. · 2016 [cited by applicant]
US 20130243750A1 · Scheerens et al. · 2013 [cited by applicant]
US 20140275492A1 · Sutkowski · 2014 [cited by applicant]
US 20140315252A1 · Endl et al. · 2014 [cited by applicant]
US 20160157468A1 · Cogne et al. · 2016 [cited by applicant]
WO WO2012072678 · 2012 [cited by applicant]
WO WO2016149137 · 2016 [cited by applicant]
Rudikoff et al. (1982). PNAS. 79:1979-1983. [cited by examiner]
Achatz, Gernot, Lars Nitschke, and Marinus C. Lamers. “Effect of transmembrane and cytoplasmic domains of IgE on the IgE response.” [cited by applicant]
Avery, Danielle T., et al. “STAT3 is required for IL-21-induced secretion of IgE from human naive B cells.” [cited by applicant]
Fitzsimmons, Colin Matthew, Franco Harald Falcone, and David W. Dunne. “Helminth allergens, parasite-specific IgE, and its protective role in human immunity.” [cited by applicant]
International Preliminary Report on Patentability issued in International Application No. PCT/US2018/015870, mailed Aug. 15, 2019. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2018/015870, mailed Jun. 20, 2018. [cited by applicant]
Invitation to pay additional fees issued in International Application No. PCT/US2018/015870, mailed Apr. 10, 2018. [cited by applicant]
Karnowski, Alexander, et al. “Inefficient processing of mRNA for the membraneform of IgE is a genetic mechanism to limit recruitment of IgE-secreting cells.” [cited by applicant]
Pomés et al., “First Naturally Occurring Human IgE Antibody Against Mite Allergen Der p 2”, Abstract from AAAAI Annual Meeting, Mar. 2017. [cited by applicant]
Pomés et al., “Human IgE monoclonal antibodies with natural heavy and light chain pairing and specificity for asthma-associated allergens”, Abstract from EAACI Annual Meeting, Jun. 2017. [cited by applicant]
Renz, H. A. R. A. L. D., Bruce D. Mazer, and Erwin W. Gelfand. “Differential inhibition of T and B cell function in IL-4-dependent IgE production by cyclosporin A and methylprednisolone.” [cited by applicant]
Shade Kai-Ting C, et al. “Sialylation of Immunoglobulin E Is a Determinant of Allergic Pathogenicity” [cited by applicant]
Smith, “Antigenic Landscape of the Human Helminth IgE Antibody Response”, NIH report for Project No. 5R01AI130459-04, dated 2020. [cited by applicant]
Smith, “Generation and Characterization of Full-Length Naturally Occurring Allergen-Specific Human IgE MABs”, NIH report for Project No. 1R21AI123307-01A1, dated 2017. [cited by applicant]
Zone, John J., et al. “IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice.” [cited by applicant]
Chen, Kuan-Wei, et al. “Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering.” [cited by applicant]
Extended European Search Report issued in European Application No. 18748576.8, mailed Nov. 5, 2020. [cited by applicant]
Braren, Ingke, et al. “Generation of human monoclonal allergen-specific IgE and IgG antibodies from synthetic antibody libraries.” [cited by applicant]
De Pascalis, Roberto, et al. “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal an… [cited by applicant]
Goel, Manisha, et al. “Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response.” [cited by applicant]
Khan, Tarique, and Dinakar M. Salunke. “Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies.” [cited by applicant]
MacCallum, Robert M., Andrew CR Martin, and Janet M. Thornton. “Antibody-antigen interactions: contact analysis and binding site topography.” [cited by applicant]
Mariuzza, R. A., S. E. Phillips, and R. J. Poljak, “The structural basis of antigen-antibody recognition.” [cited by applicant]
Piche-Nicholas, Nicole M., et al. “Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.” [cited by applicant]
Poosarla, Venkata Giridhar, et al. “Computational de novo design of antibodies binding to a peptide with high affinity,” [cited by applicant]
Rader, Christoph, David A. Cheresh, and Carlos P. Barbas III. “A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries.” [cited by applicant]
Uhlemann, L., W-M. Becker, and M. Schlaak. “Food allergy: Identification and characterization of peanut allergens with patients' sera and monoclonal antibodies.” [cited by applicant]
Caldas, Cristina, et al. “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen.” [cited by applicant]
Casadevall, Arturo, and Alena Janda. “Immunoglobulin isotype influences affinity and specificity.” [cited by applicant]
Du, Jiamu, et al. “Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis.” [cited by applicant]
Kunik, Vered, Bjoern Peters, and Yanay Ofran. “Structural consensus among antibodies defines the antigen binding site.” [cited by applicant]
Office Communication issued in European Application No. 18748576.8, dated Oct. 17, 2024. [cited by applicant]
Sela-Culang, Inbal, Vered Kunik, and Yanay Ofran. “The structural basis of antibody-antigen recognition.” [cited by applicant]
Winkler, Karsten, et al. “Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody.” [cited by applicant]